Biotech Startups
topic on 6 shows · 9 statements across 9 episodes
the Y Combinator Startup Podcast 
Cheeky Pint 
American Optimist 
No Priors 
the a16z Podcast 
All-In
9 statements about Biotech Startups, every show
Hershberg: Biotech startups generate two-thirds of newly approved drugs
“Biotech startups now make two thirds of the drugs that go to market.”
Wickramasekara: Large pharma generates model-training data at scale startups cannot match
“They can generate data to train their own models at a scale that most biotech startups can't match.”
Ricks: Early-stage biotechs pitch 80% to 100% of revenue from the US
“If you fund, if you went out and said, hey, I want to back some biotechs, and they sent you their business plan, 80 to a hundred percent of the revenue in return they'll pitch you on is the US. Meaning there is no return outside the US if you start at the poin…”
Gimenez: Decentralized biotech enables curing long-tail rare diseases centralized systems ignore
“If you think about that same model of like this long tail, it can be profitable if you think at a global scale, and we actually reduce the cost to actually start these kinds of innovations and distribute them to people. And think about that in the context of d…”
Friedberg: 50 protein-folding startups will be funded in 12-18 months
“I think we're within, within one year, J. Cal, of a lot of startups replicating this alpha fold technique, and then using that to go do drug discovery, and you'll see 50 startups getting funded 12 to 18 months from now based on some novel protein idea.”
Biotech Boards Increasingly Retain U.S. Rights and Out-License Ex-U.S. Rights
“What we've seen really over the last 10 years is a lot of boards want the companies to be able to be standalone. And so, what you see are, in this fairly typical and actually Spark is a good example, where the company will keep commercial rights for the U.S. A…”
Iorns: Biotech spinouts rely too much on figurehead principal investigators for funding
“I think that's still very difficult for scientists, particularly PhD and postdoc scientists, so they actually make the discoveries in these labs, so they're the ones doing the work but a lot of the time for them to actually be the ones to be the founder of the…”
Buchheit: Biotech risk is technical feasibility, not market demand
“The risk on those companies is, is, is most often not market risk. It's not the risk that no one wants a cure for cancer. The risk is that they don't actually have a cure for cancer, right? So, so with those companies, more often, it's one of these things wher…”
Iorns: Pharma companies source innovation primarily by buying clinical-stage biotechs
“The pharma companies are desperate for buying in innovation, and so they're really looking for companies to get to that initial proof of concept in a human, in human studies. So that, that's really where a lot of their innovation is coming from, is biotechs th…”